Editas Medicine: Jim Mullen
Jim Mullen has been appointed as CEO of Editas Medicine, where he will replace Cindy Collins. He will take up his new post Feb. 15 and will continue to serve as chairman of the company's board of directors, a role he assumed in March 2018. Previously, Mullen was CEO and a director of Patheon, a contract development and manufacturing organization that was acquired by Thermo Fisher Scientific in 2017. Prior to that, he was president and CEO of Biogen, where he previously held various other positions, including chief operating officer, VP international, and VP of operations. He is also a member of the board of the directors of Thermo Fisher Scientific. Mullen holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.